Introduction: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Despite long-term survival rates of 85~90% for newly diagnosed patients(pts) in children with ALL, approximately 20% of pts experience relapsed or refractory (R/R) disease. These R/R ALL cases have poor prognoses, remaining a significant cause of mortality among children.
Inaticabtagene Autoleucel(Inati-cel) is an autologous CD19 CAR-T therapy first approved by the NMPA in 2023 for adult pts with R/R B-cell ALL. The safety and efficacy of Inati-cel in children with R/R B-cell ALL are not yet established.
Methods: The trial (NCT05667506) in Chinese children aged 3-18 years with R/R B-cell ALL is a single-arm, phase Ib/II, multicenter, open-label study. Pts underwent leukapheresis to obtain T cells for Inati-cel manufacturing. They received a single infusion of Inati-cel at a target dose of 1×106 CAR + viable T-cells/kg (±20%) after lymphodepletion with cyclophosphamide and fludarabine. The primary objectives were to assess the safety, dose-limiting toxicities (DLTs), and the recommended dose in pivotal trial; The primary efficacy endpoint was the overall response rate (ORR) of complete response (CR) and CR with incomplete hematological recovery (CRi) within three months post-infusion.
Results: From April 3, 2023, to June 14, 2024, 17 pts were enrolled and underwent leukapheresis, with no manufacturing failure reported. Twelve pts received Inati-cel infusion and had at least one efficacy assessment. The median age was 12.5 years (range: 6-17). Among the 12 pts diagnosed with B-cell ALL, 25.0% (3/12) were primary refractory, and 66.7% (8/12) had relapsed or refractory after median 2 lines prior therapies, and 1 patient (8.3%) had an early relapse (<18 months from diagnosis). Bone marrow (BM) blasts before infusion ranged from 5.0% to 97.5%, with 41.7% (5/12) having >50% blasts.
All 12 pts (100%) achieved response including CR (N=6, 50.0%) or CRi (N=6, 50.0%) at 28 days post-infusion, all (100%) being Minimal Residual Disease (MRD) negative. With a median follow-up of 2.0 months (range: 0.9+ to 13.3+), 5 pts maintained a response for at least three months with sustained MRD negativity, and no relapse were reported;11 pts remained alive. One patient withdrew at two months post-infusion and died of cardiogenic shock during conditioning therapy before HSCT. Median duration of remission (DOR), relapse-free survival (RFS), and overall survival (OS) have not been reached.
No unexpected or fatal adverse events (AEs) were reported during follow-up. The most frequent Grade ≥3 treatment-emergent AEs were hematologic toxicity. CRS occurred in 91.7% of pts (N=11), with one patient experiencing Grade≥3 CRS, The median CRS onset was seven days (range: 2-10) and lasted seven days (range: 2-34). Two pts experienced Grade 3-4 ICANS, with a median onset of 10.5 days (range: 9-12) and a median duration of 14 days (range: 10-18). All CRS and ICANS cases were resolved without sequelae. Among the 6 pts in the phase Ib stage, one patient had a DLT event observed, related to high tumor burden and severe Grade 4 CRS, and was deemed manageable by the Steering Committee.
CAR T-cell expansion occurred in all pts with a median time to maximum expansion (T max ) of 15 days (range: 9-23), and a peak copy number (Cmax) of 1.24×105 copies/μg gDNA.
Conclusion: This trial demonstrates that Inati-cel is safe and effective in heavily treated children with R/R B-cell ALL. A pivotal trial evaluating Inati-cel at a target dose of 1×10^6 cells/kg (±20%) in children with R/R B-ALL is underway.
*On behalf of Copenhagen Hospital Biobank and International Epidemiology Lymphoma Consortium
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal